Despite Advances in Technology, Regenerative Medicine Field Still Faces Great Hurdles on the Road to Commercialization

0

Rate this Article: (3.5 Stars | 2 Votes)   Thanks for your rating!

IQPC’s Commercialization of Regenerative Medicine Conference focuses on surmounting challenges faced by the industry

PHILADELPHIA, PA – Pharma IQ, a division of IQPC, announces the Commercialization of Regenerative Medicine Conference, being held December 12 to 13, 2011 in Philadelphia, PA. The regenerative medicine field has potential to become the most lucrative area of modern medicine, but many barriers exist before market potential can be fully achieved. The conference investigates major hurdles companies moving into the space need to overcome including funding, research, quality control, gatekeeper approval, scale-up issues and acceptance by the medical field.

There are currently over 2,000 clinical trials linked to cell therapies, however there are significant commercialization challenges to surmount before companies see any return on their investments. The path to commercialization includes optimization of clinical development, negotiating reimbursement, overcoming strategic and regulatory challenges, and navigating partnership opportunities. Speaking on the commercial manufacturing scale-up process and some factors involved in the process, William Fodor, Director of Translational Sciences, Cell Therapy Group, noted the many approval processes and pitfalls to be aware of within the scale-up process. Read the interview in its entirety here:
http://www.regenerativemedicinesummit.com/redForms.aspx?id=603506&sform_id=620060&MAC=20833.001_SMedia_AS

Some specific aspects of the commercialization of regenerative medicine addressed on the conference agenda include:

• Approval processes and pitfalls within the scale-up process
• Developing a sound business plan
• Case studies from companies who have successfully raised funds
• Using stem cells in a commercial and industrial setting
• Analysis of regulatory pathways and pre-market approval
• Panel discussions comparing four evolving business models

Featured speakers include industry leaders Claudia Zylberberg, PhD, President and CEO of Akron Biotechnology; Rahul Aras, CEO of Juventas Therapeutics; Ira Herman, Professor and Director, Program in Cellular and Molecular Physiology Center for Innovations in Wound Healing Research at Tufts University School of Medicine; Madhusudan Peshwa, Executive Vice-President of Cellular Therapies at Maxcyte, Inc. and more.

For more information on the Commercialization of Regenerative Medicine Conference please visit www.regenerativemedicinesummit.com or contact Robert Littlefield, Program Director at Robert.Littlefield@iqpc.com.

About IQPC

IQPC (www.iqpc.com) provides business executives with tailored practical conferences, large-scale events, topical seminars and in-house training programs. Producing over 1,500 events annually around the world, IQPC continues to grow and has offices in cities across six continents including: Berlin, Dubai, London, New York, Sao Paulo, Singapore, Sydney, and Toronto.

Contact:
IQPC
Taryn Soltysiak
T: +1 646-200-7945
F: +1 888-231-7864
www.iqpc.com

Contributor:   Pharma IQ News

You Should Check Out:

Commercialisation of Regenerative Medicine

Bringing Innovation to Clinical Design